35 results
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
& Technology Committee (c): Committee Chair * = New Director since 2020
8 Overview of 2024 Director Nominees Skills, Age & Tenure All Director
DFAN14A
MRTX
Mirati Therapeutics Inc
10 Oct 23
Additional proxy materials by non-management
6:48am
shareholders, the Mirati transaction is aligned with our business development goals. Importantly, by leveraging our skills and capabilities, including our … skills and capabilities, including our global commercial infrastructure, will allow us to bring Mirati’s portfolio of medicines to as many patients
DEFA14A
q617m7phdktge1s4ys
10 Apr 23
Additional proxy soliciting materials
5:12pm
DEFA14A
apep6gt jmj2ev
20 Apr 22
Additional proxy soliciting materials
4:30pm
SC TO-C
EX-99.7
ze2dyfha
5 Oct 20
Information about tender offer
5:13pm
SC TO-C
EX-99.3
5r8c3o0nh18r so748r
5 Oct 20
Information about tender offer
5:13pm
SC TO-C
EX-99.6
5uebzu7fg j5u3
5 Oct 20
Information about tender offer
5:13pm
8-K
EX-99.1
u2ievafsf7owh41
7 May 20
Bristol Myers Squibb Reports Strong First Quarter 2020 Financial Results
8:08am
DEFA14A
p24v3 ob8yxb8
23 Apr 20
Additional proxy soliciting materials
8:59am
425
wiot9wt
19 Mar 19
Business combination disclosure
7:04am
425
479awq2n
6 Mar 19
Business combination disclosure
7:03am